Abstract
Novel oxygen-incorporated SAHA (oxa-SAHA) analogues, in which oxygen was inserted in the alkyl linker connecting the hydroxamic acid moiety and amide group, were synthesized and their inhibitory activities on histone deacetylase were evaluated. The most active oxa-SAHA analogue potently inhibited histone deacetylase, almost as potently as SAHA. Various structural modifications in the amide, but not the hydroxamic acid, significantly affected the inhibitory activities of the derivatives. Based on the inhibitory data, the N-phenyl moiety of the amide turned to be a better modification site for enhancing the inhibitory activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Grozinger, C. M. and Schreiber, S. L., Deacetylase enzymes: Biological functions and the use of small-molecule inhibitors. Chem. Biol., 3–16 (2002).
Kouzarides, T., Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev., 40–48 (2002).
Hassig, C. A. and Schreiber, S. L., Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr. Opin. Chem. Biol., 300–308 (1997).
Sheeba, V., Deepak, G., Tiffany, B., Anchalee, J., Steven, D. G., Robert, A. C. Jr., and Patrick, M. W., Alkyl-substituted polyaminohydroxamic acids: A novel class of targeted histone deacetylase inhibitors. J. Med. Chem., 48, 6350–6365 (2005).
Olaia, M.-I., Lidia, R.-L., Ruth, S.-M., Laura, G., Alberto, Z., and Ana, A., Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin. Transl. Oncol., 10, 395–398 (2008)
Meinke, P. T. and Liberator, P., Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Curr. Med. Chem., 8, 211–235 (2001).
Breslow, R., Belvedere, S., and Gershell, L., Development of cytodifferentiating agents for cancer chemotherapy. Helv. Chim. A., 83, 1685 (2000).
Takayoshi, S., Yuki, N., Akiyasu, K., Azusa, M., Sakiko, M., Mineko, K., Hidehiko, N., and Naoki, M., Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J. Med. Chem., 48, 1019–1032(2005).
Ocker, M., Alajati, A., Ganslmayer, M., Zopt, S., Lüders, M., Neureiter, D., Hahn, E. G., Schuppan, D., and Herold, C., The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J. Cancer Res. Clin. Oncol., 131, 385–394 (2005).
Stacy, W. R., Lidia, C. S., Peter, A., Kenneth, W. B., Wendy, D. C., Michael, A. G., Kobporn, L. H., Manfred, J., Paul, K., Nancy, T., and Heather, W., Inhibitors of human histone deacetylase: Synthesis and enzyme and cellular activity of straight chain hydroxamates. J. Med. Chem., 45, 753–757 (2002).
Conejo-Garcia, A. and Schofield, C., A prodrug system for hydroxylamines based on esterase catalysis. Bioorg. Med. Chem. Lett., 15, 4004–4009 (2005).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, SA., Jin, Y.L. & Kim, H.S. Structure-activity relationship studies of novel oxygen-incorporated SAHA analogues. Arch. Pharm. Res. 32, 15–21 (2009). https://doi.org/10.1007/s12272-009-1113-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-009-1113-5